Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...

PATINA supports adding palbociclib to anti-HER2 plus endocrine therapy in HR+/HER2+ disease, and HER2CLIMB-05 validates tucatinib with HP after THP induction. Sequencing trials must address ADC ...

A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive ...

A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive procedure ...

Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...

Cancers of the reproductive and urinary organs, known as genitourinary cancers, affect millions of people worldwide each year ...